IBI Cancer Research Results

IBI, Intestinal Barrier Integrity: Click to Expand ⟱
Source:
Type:

Intestinal Barrier Integrity (IBI) refers to the functional integrity of the gut mucosal barrier, including epithelial tight junctions, mucus protection, antimicrobial defenses, and control of luminal antigen and microbial translocation. Loss of intestinal barrier integrity increases permeability, promotes endotoxin and cytokine-driven inflammation, and can sustain tumor-supportive signaling through NF-κB, STAT3, oxidative stress, and immune dysregulation. In IBD, barrier disruption is a core pathogenic feature that amplifies chronic mucosal inflammation and tissue injury. In cancer, especially colorectal cancer, persistent barrier dysfunction may contribute to initiation, progression, and a pro-inflammatory microenvironment, although in some treatment contexts increased permeability can also alter drug exposure or immune interactions. Agents that improve intestinal barrier integrity may be relevant in IBD-associated carcinogenesis and in reducing inflammation-linked tumor promotion.

Related terms/synonyms: gut barrier, epithelial barrier, mucosal barrier, intestinal permeability, leaky gut.
Scientific Papers found: Click to Expand⟱
5932- CAR,    Carvacrol attenuates mucosal barrier impairment and tumorigenesis by regulating gut microbiome
- in-vivo, IBD, NA - in-vivo, Park, NA
*GutMicro↑, Risk↓, *Inflam↓, *antiOx↓, *ZO-1↑, *iNOS↓, *IL6↓, *NO↓, *PGE2↓, *memory↑, *TLR4↓, *NF-kB↓, *IBI↑, *CLDN3↑, *CLDN1↑, *MUC1↑, *OCLN↑, *iNOS↑, *COX2↓, *IFN-γ↓, IL1β↓, ADAM10?,
6023- CGA,    Pharmacological advances of the chlorogenic acids family: current insights and future research directions
- Review, AD, NA - Review, Park, NA - Review, IBD, NA
*Aβ↓, *neuroP↑, *cardioP↑, *GastroP↑, *RenoP↑, *hepatoP↑, *Obesity↓, *Bacteria↓, *BioAv↑, *BioAv↑, *BioAv↑, *ROS↓, *GutMicro↑, *IBI↑, *MCT1↓, *NF-kB↓, *DNMT1↓,
5934- TV,    Protective Effects of Natural Antioxidants on Inflammatory Bowel Disease: Thymol and Its Pharmacological Properties
- Review, Var, NA
*Inflam↓, *antiOx↑, *Bacteria↓, AntiTum↑, *toxicity∅, *IBI↑, *ZO-1↑, *OCLN↑, *COX1↑, *TLR4↓, *NF-kB↓, *TNF-α↓, *IL1β↓, *TAC↑, *NRF2↑, *GutMicro↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Immune & Inflammatory Signaling ⓘ

IL1β↓, 1,  

Synaptic & Neurotransmission ⓘ

ADAM10?, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   Risk↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   NRF2↑, 1,   ROS↓, 1,   TAC↑, 1,  

Cell Death ⓘ

iNOS↓, 1,   iNOS↑, 1,   MCT1↓, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 1,  

Migration ⓘ

CLDN1↑, 1,   MUC1↑, 1,   ZO-1↑, 2,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

CLDN3↑, 1,   GastroP↑, 1,   IBI↑, 3,   OCLN↑, 2,  

Immune & Inflammatory Signaling ⓘ

COX1↑, 1,   COX2↓, 1,   IFN-γ↓, 1,   IL1β↓, 1,   IL6↓, 1,   Inflam↓, 2,   NF-kB↓, 3,   PGE2↓, 1,   TLR4↓, 2,   TNF-α↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,  

Clinical Biomarkers ⓘ

GutMicro↑, 3,   IL6↓, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 1,   Obesity↓, 1,   RenoP↑, 1,   toxicity∅, 1,  

Infection & Microbiome ⓘ

Bacteria↓, 2,  
Total Targets: 39

Scientific Paper Hit Count for: IBI, Intestinal Barrier Integrity
1 Carvacrol
1 Chlorogenic acid
1 Thymol-Thymus vulgaris
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1462  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page